journal article·2020-07-13Open access

Polymeric Biomaterial Scaffolds for Tumoricidal Stem Cell Glioblastoma Therapy

Kathryn M. Moore, Ananya B. Murthy, Elizabeth G. Graham-Gurysh, Shawn D. Hingtgen, Eric M. Bachelder, Kristy M. Ainslie

Abstract

Glioblastoma (GBM) is the most common primary brain tumor and has a poor prognosis; as such, there is an urgent need to develop innovative new therapies. Tumoricidal stem cells are an emerging therapy that has the potential to combat limitations of traditional local and systemic chemotherapeutic strategies for GBM by providing a source for high, sustained concentrations of tumoricidal agents locally to the tumor. One major roadblock for tumoricidal stem cell therapy is that the persistence of tumoricidal stem cells injected as a cell suspension into the GBM surgical resection cavity is limited. Polymeric biomaterial scaffolds have been utilized to enhance the delivery of tumoricidal stem cells in the surgical resection cavity and extend their persistence in the brain, ultimately increasing their therapeutic efficacy against GBM. In this review, we examine three main scaffold categories explored for tumoricidal stem cell therapy: microcapsules, hydrogels, and electrospun scaffolds. Furthermore, considering the significant impact of surgery on the brain and recurrent GBM, we survey a brief history of orthotopic models of GBM surgical resection.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Neurogenesis and neuroplasticity mechanisms · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, North Carolina 27599, United States

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States

Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States

Funding

National Institute of Neurological Disorders and Stroke · Division of Graduate Education

References (100+)

Show source-provided references
1. 10.1093/neuonc/noy13110.1093/neuonc/noy131 ↗
2. 10.12688/f1000research.11493.110.12688/f1000research.11493.1 ↗
3. 10.3892/ol.2017.625110.3892/ol.2017.6251 ↗
4. 10.1007/s11060-015-2002-z10.1007/s11060-015-2002-z ↗
5. 10.1016/j.surg.2011.07.04410.1016/j.surg.2011.07.044 ↗
6. 10.5732/cjc.013.1020710.5732/cjc.013.10207 ↗
7. 10.1186/s40169-018-0211-810.1186/s40169-018-0211-8 ↗
8. 10.1016/j.drup.2015.02.00210.1016/j.drup.2015.02.002 ↗
9. Tamargo R. J. · Cancer Res. · 1993 · 53 · 329
10. 10.4155/tde.14.11410.4155/tde.14.114 ↗
11. 10.1586/14737140.2013.84009010.1586/14737140.2013.840090 ↗
12. Fung L. K. · Cancer Res. · 1998 · 58 · 672
13. 10.1016/j.clineuro.2012.04.00510.1016/j.clineuro.2012.04.005 ↗
14. 10.2165/00003088-200241060-0000210.2165/00003088-200241060-00002 ↗
15. 10.1185/0300799080250818010.1185/03007990802508180 ↗
16. 10.1016/j.jconrel.2017.12.02010.1016/j.jconrel.2017.12.020 ↗
17. 10.1007/s40262-015-0319-610.1007/s40262-015-0319-6 ↗
18. 10.1007/s11095-017-2114-610.1007/s11095-017-2114-6 ↗
19. Yang M. B. · Cancer Res. · 1989 · 49 · 5103
20. 10.1073/pnas.97.23.1284610.1073/pnas.97.23.12846 ↗
21. 10.1038/nrc379810.1038/nrc3798 ↗
22. 10.1002/sctm.18-000310.1002/sctm.18-0003 ↗
23. 10.1186/s13287-018-0977-z10.1186/s13287-018-0977-z ↗
24. 10.1016/S0736-5748(99)00052-010.1016/S0736-5748(99)00052-0 ↗
25. 10.1002/1097-0142(197806)41:6<2431::AID-CNCR2820410650>3.0.CO;2-310.1002/1097-0142(197806)41:6<2431::AID-CNCR2820410650>3.0.CO;2-3 ↗
26. 10.1001/archinte.1990.0039013014502310.1001/archinte.1990.00390130145023 ↗
27. 10.1007/s11060-005-9071-310.1007/s11060-005-9071-3 ↗
28. 10.2147/IJN.S5257710.2147/IJN.S52577 ↗
29. 10.1038/8347110.1038/83471 ↗
30. Read T. A. · Cancer Res. · 2001 · 61 · 6830
31. 10.1038/8348110.1038/83481 ↗
32. 10.1093/neuonc/not05410.1093/neuonc/not054 ↗
33. 10.1096/fj.09-13188810.1096/fj.09-131888 ↗
34. 10.3109/02652048.2011.59944110.3109/02652048.2011.599441 ↗
35. 10.1016/j.biomaterials.2016.01.00710.1016/j.biomaterials.2016.01.007 ↗
36. 10.1016/j.biomaterials.2016.03.00810.1016/j.biomaterials.2016.03.008 ↗
37. 10.1093/neuonc/noq00210.1093/neuonc/noq002 ↗
38. 10.1038/nn.301910.1038/nn.3019 ↗
39. 10.1016/j.ymthe.2020.02.00810.1016/j.ymthe.2020.02.008 ↗
40. 10.1016/j.msec.2020.11084610.1016/j.msec.2020.110846 ↗
41. 10.1038/ncomms1059310.1038/ncomms10593 ↗
42. 10.1126/scitranslmed.aah651010.1126/scitranslmed.aah6510 ↗
43. 10.1158/0008-5472.CAN-04-187410.1158/0008-5472.CAN-04-1874 ↗
44. 10.1593/neo.342710.1593/neo.3427 ↗
45. 10.1126/scitranslmed.300536510.1126/scitranslmed.3005365 ↗
46. 10.1186/s12885-019-6460-010.1186/s12885-019-6460-0 ↗
47. 10.1016/j.canlet.2013.02.01910.1016/j.canlet.2013.02.019 ↗
48. 10.15171/apb.2019.06310.15171/apb.2019.063 ↗
49. 10.1073/pnas.080664710610.1073/pnas.0806647106 ↗
50. 10.1016/j.neuron.2011.05.00710.1016/j.neuron.2011.05.007 ↗
51. 10.1186/s13287-019-1163-710.1186/s13287-019-1163-7 ↗
52. 10.1016/j.stem.2012.02.02110.1016/j.stem.2012.02.021 ↗
53. 10.1158/1078-0432.CCR-16-151810.1158/1078-0432.CCR-16-1518 ↗
54. 10.1007/s11060-016-2110-410.1007/s11060-016-2110-4 ↗
55. 10.1056/NEJMra070812610.1056/NEJMra0708126 ↗
56. 10.1016/j.wneu.2011.06.05310.1016/j.wneu.2011.06.053 ↗
57. 10.1007/s11064-019-02864-810.1007/s11064-019-02864-8 ↗
58. 10.18632/oncotarget.1455310.18632/oncotarget.14553 ↗
59. 10.1007/s11060-016-2096-y10.1007/s11060-016-2096-y ↗
60. 10.1093/neuonc/now11710.1093/neuonc/now117 ↗
61. 10.1007/s11095-009-9945-810.1007/s11095-009-9945-8 ↗
62. 10.4049/jimmunol.174.2.63610.4049/jimmunol.174.2.636 ↗
63. 10.1523/JNEUROSCI.0546-15.201510.1523/JNEUROSCI.0546-15.2015 ↗
64. 10.1023/A:100757640503910.1023/A:1007576405039 ↗
65. Bello L. · Clin. Cancer Res. · 2002 · 8 · 3539
66. 10.1007/s11060-012-1008-z10.1007/s11060-012-1008-z ↗
67. 10.1007/s11060-012-1008-z10.1007/s11060-012-1008-z ↗
68. 10.1016/j.jneumeth.2017.04.01910.1016/j.jneumeth.2017.04.019 ↗
69. 10.1007/s11060-009-9857-910.1007/s11060-009-9857-9 ↗
70. 10.3791/5745210.3791/57452 ↗
71. 10.1158/1078-0432.CCR-17-007710.1158/1078-0432.CCR-17-0077 ↗
72. 10.1038/jcbfm.2009.21910.1038/jcbfm.2009.219 ↗
73. 10.3727/09602019838993310.3727/096020198389933 ↗
74. 10.1016/j.biomaterials.2013.04.04710.1016/j.biomaterials.2013.04.047 ↗
75. 10.1002/term.15410.1002/term.154 ↗
76. 10.2147/IJN.S17591410.2147/IJN.S175914 ↗
77. 10.1016/j.biomaterials.2016.03.02010.1016/j.biomaterials.2016.03.020 ↗
78. 10.1517/14712598.3.4.55110.1517/14712598.3.4.551 ↗
79. 10.1016/j.neures.2011.12.00510.1016/j.neures.2011.12.005 ↗
80. 10.1146/annurev.biochem.77.032207.12083310.1146/annurev.biochem.77.032207.120833 ↗
81. 10.2174/092986732466617051112310110.2174/0929867324666170511123101 ↗
82. 10.1002/jnr.2415110.1002/jnr.24151 ↗
83. 10.1111/j.1750-3639.2008.00195.x10.1111/j.1750-3639.2008.00195.x ↗
84. 10.1161/ATVBAHA.117.30856410.1161/ATVBAHA.117.308564 ↗
85. 10.1016/j.progpolymsci.2011.06.00310.1016/j.progpolymsci.2011.06.003 ↗
86. 10.1007/s10529-006-9156-x10.1007/s10529-006-9156-x ↗
87. 10.1016/j.msec.2017.03.26410.1016/j.msec.2017.03.264 ↗
88. 10.1007/s10856-019-6318-710.1007/s10856-019-6318-7 ↗
89. 10.1016/j.actbio.2018.09.02010.1016/j.actbio.2018.09.020 ↗
90. 10.1016/j.biomaterials.2015.10.02410.1016/j.biomaterials.2015.10.024 ↗
91. 10.1016/j.jare.2013.07.00610.1016/j.jare.2013.07.006 ↗
92. 10.1002/sctm.16-011610.1002/sctm.16-0116 ↗
93. 10.1177/154596831036195810.1177/1545968310361958 ↗
94. 10.1039/C8BM01246F10.1039/C8BM01246F ↗
95. 10.1016/j.actbio.2017.01.06010.1016/j.actbio.2017.01.060 ↗
96. 10.1093/jnci/dju09010.1093/jnci/dju090 ↗
97. 10.1038/mt.2014.20410.1038/mt.2014.204 ↗
98. TISSEEL [Fibrin Sealant] Full Prescribing Information https://baxterpi.com/pi-pdf/Tisseel_PI.pdf.
99. 10.1016/j.addr.2014.01.01010.1016/j.addr.2014.01.010 ↗
100. 10.1016/j.biomaterials.2008.01.01110.1016/j.biomaterials.2008.01.011 ↗